Thursday, March 23, 2023
This article is intended for primary care physicians, addiction specialists, psychiatrists, hepatologists, and other specialists who care for patients with alcoholism.
The goal of this activity is to provide the latest medical news to physicians and other healthcare professionals in order to enhance patient care.
Upon completion of this activity, participants will be able to:
As an organization accredited by the ACCME, Medscape requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as "financial relationships in any amount, occurring within the past 12 months," that could create a conflict of interest.
Medscape encourages Authors to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration, at first mention and where appropriate in the content.
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape designates this educational activity for 0.25 category 1 credit(s) toward the AMA Physician's Recognition Award. Each physician should claim only those credits that reflect the time he/she actually spent in the activity.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 5 years; at any point within this time period you can print
out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.
*The credit that you receive is based on your user profile.
CME Released: 4/5/2005
Valid for credit through: 4/5/2006
processing....
April 5, 2005 — A depot form of naltrexone given once per month can significantly reduce the rate of heavy drinking in patients with alcohol dependence, according to the results of a six-month, double-blind, randomized study published in the April 6 issue of JAMA.
"Naltrexone, an opioid antagonist, has been shown to be effective for treatment of alcohol dependence," write James C. Garbutt, MD, from the University of North Carolina School of Medicine in Chapel Hill, and colleagues from the Vivitrex Study Group. "However, adherence to daily oral pharmacotherapy can be problematic, and clinical acceptance and utility of oral naltrexone have been limited."
Between February 2002 and September 2003, 899 individuals were screened at 24 U.S. public hospitals, private and Veterans Administration clinics, and tertiary care medical centers. Of the 899 individuals who were screened, 627 were diagnosed as being actively drinking alcohol-dependent adults and were randomized to receive treatment, and 624 received at least one injection.
The treatment groups consisted of an intramuscular injection of 380 mg of long-acting naltrexone (n = 205), of 190 mg of long-acting naltrexone (n = 210), or of a matching volume of placebo (n = 209). Each injection was given monthly, along with 12 sessions of low-intensity psychosocial intervention. Analysis was by intent-to-treat, and the primary outcome was the event rate of heavy drinking days.
Compared with placebo, 380 mg of long-acting naltrexone was associated with a 25% decrease in the event rate of heavy drinking days ( P = .03), and 190 mg of naltrexone was associated with a 17% decrease ( P = .07). Treatment effects were greater in men and in those with lead-in abstinence.
Discontinuation because of adverse events occurred in 14.1% of those assigned to 380 mg of naltrexone, in 6.7% of those assigned to 190 mg of naltrexone, and in 6.7% of those assigned to placebo. There was no evidence of hepatotoxicity. Overall, rate and time to treatment discontinuation were similar in all three groups.
"Long-acting naltrexone was well tolerated and resulted in reductions in heavy drinking among treatment-seeking alcohol-dependent patients during six months of therapy," the authors write. "These data indicate that long-acting naltrexone can be of benefit in the treatment of alcohol dependence."
Study limitations include the possibility that patients enrolled in this trial may have had more motivation for change than patients treated in traditional outpatient settings; lack of drinking data for dropouts once they left the study; and inability to address why the results differed in men and in women.
"Since no single treatment will reduce completely the risk of heavy drinking among all alcohol-dependent patients, we believe that an important clinical benefit of long-acting naltrexone is that it provides a firm basis for combination with other treatments, including psychotherapy, other medications, or both," the authors conclude. "Additional research is needed to determine the optimal duration of treatment with long-acting naltrexone, as well as indicators that treatment can be discontinued."
Alkermes funded this study and employs three of its authors. Some of the other authors report various financial arrangements with Bristol-Meyers Squibb, Alkermes, Oy ContrAl Pharma, Forest Laboratories, Wyeth-Ayerst, Drug Abuse Sciences, Ortho-McNeil Pharmaceuticals, Pfizer, DuPont, Lipha, Johnson & Johnson, AstraZeneca, Eli Lilly, Lipha-Merck-KGaA, Axis-Shield, and/or Titan.
JAMA. 2005;293:1617-1625
